Completed PHASE4 INTERVENTIONAL NCT00465933

Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)

Treatment of Acute Promyelocytic Leukemia: Remission Induction With ATRA + Idarubicin (AIDA) Risk Adapted Intensity of Consolidation and Addition of ATRA Maintenance With ATRA + Methotrexate + Mercaptopurine Salvage Therapy for Molecular and Haematological Relapses

Sponsor: PETHEMA Foundation

Conditions Acute Promyelocytic Leukemia

Interventions AIDA

Updated 5 times since 2017 Last updated: Mar 27, 2008 Started: Mar 31, 1999 Primary completion: Aug 31, 2007 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Acute Promyelocytic Leukemia and is currently completed. PETHEMA Foundation leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PETHEMA Foundation

Data source: PETHEMA Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basurto, Spain
• Valencia, Spain